2-Amino-benzoxazole sulfonamides as HIV protease inhibitors

Abstract

Several pharmaceutical companies have developed an increasing number of second generation protease inhibitors (PIs) during the last few years. These compounds have been used in the preclinical arena or are at the beginning of their clinical use. All drugs in this category have been designed to be well absorbed and overcome the crucial problem of cross-resistance within this class of compounds. Due to the likelihood of PI cross-resistance, new active PIs for treating HIV-1 infection will be eagerly needed. In this patent, Tibotec Pharm. presents a new class of 2-amino-benzoxazole sulfonamide compounds that are active in inhibiting HIV-1 infection, including the one mediated by multi-drug resistant isolates.

• antiretrovirals
• drug resistance
• HIV-1
• protease inhibitors (PIs)
• sulfonamide